文献速递肝肾功能剂量调整特殊人群用药

腹膜透析老年患者潜在不适当处方药物暴露的患病率

Prevalence of potentially inappropriately prescribed medications among older adults receiving peritoneal dialysis.
PubMed 文献 · Pharmacotherapy · 2025-03-04

本研究基于美国肾脏数据系统回顾性分析2018年起始腹膜透析的3760例65岁以上Medicare Part D参保患者,评估根据肾功能调整剂量标准判定为超治疗剂量或禁忌药物的潜在不适当处方药物(PIPM)暴露情况。结果显示,28%的患者在透析开始时暴露于PIPM,至第一年末仍有21.8%暴露;用药≥4种者暴露风险显著升高。研究提示需建立药物管理项目以减少PIPM暴露。

要点

  • 约28%的腹膜透析老年患者起始透析时暴露于PIPM,第一年末仍有21.8%暴露。
  • 用药种类≥4种者暴露于PIPM的比值比是<4种者的2.8-14.1倍。
  • 糖尿病诊断、居住在美国南部也与PIPM暴露风险升高相关。

核心结论

  • 约20%-30%的腹膜透析患者在第一年暴露于PIPM,支持建立药物管理项目以减少此类暴露。

研究设计与样本

  • 回顾性纵向队列分析,数据来自美国肾脏数据系统,纳入2018年起始腹膜透析、年龄>65岁、连续参加Medicare Part D 12个月且起始透析时使用≥1种药物的患者3760例。

主要发现

  • 起始透析时28%的患者暴露于PIPM,第一年末仍有21.8%暴露。
  • 用药≥4种 vs <4种的患者暴露于PIPM的比值比为2.8-14.1倍(P<0.001)。
  • 年龄≥85岁 vs <75岁与PIPM暴露的校正比值比为0.67(95%CI 0.48-0.95,P=0.03)。
  • 居住在美国南部 vs 东北部与PIPM暴露的校正比值比为1.30(95%CI 1.02-1.66,P=0.04)。
  • 糖尿病诊断与PIPM暴露的校正比值比为1.52(95%CI 1.29-1.78,P<0.001)。

临床怎么用

  • 对腹膜透析老年患者,尤其使用≥4种药物或合并糖尿病者,应审查是否存在超治疗剂量或禁忌药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The prevalence of exposure to supratherapeutic doses or contraindicated medications based on renal dosing criteria, also known as potentially inappropriately prescribed medications (PIPM), is currently unknown among patients on peritoneal dialysis (PD). The primary objective of this study was to evaluate the prevalence of PIPM in the first year of PD among Medicare patients in the United States. METHODS: This was a retrospective longitudinal cohort analysis of patients starting PD in 2018 in the United States Renal Data System database. Inclusion criteria were patients >65 years of age, continuously enrolled in Medicare Part D for 12 months, and prescribed ≥1 medication(s) at the start of dialysis. Prevalence of exposure to PIPM was determined at the start of dialysis and quarterly over 1 year. Logistic regression evaluated which patient characteristics (age, sex, race, Hispanic ethnicity, rurality, social deprivation index (SDI), United States region, polypharmacy, and diagnosis of diabetes and hypertension) were associated with exposure to ≥1 PIPM at the start of PD. RESULTS: There were 3760 patients included, and 28% were exposed to PIPM at the start of dialysis, and 21.8% were still exposed by the end of the first year. Patients with ≥4 versus <4 medications were at 2.8-14.1 times the odds of being exposed to PIPM (<0.001). Other key characteristics associated with exposure to PIPM were age ≥85 versus <75 years (adjusted odds ratio [aOR] 0.67, 95% confidence interval [CI] 0.48-0.95 p = 0.03), living in the South versus the Northeast (aOR 1.30 95% CI 1.02-1.66, p = 0.04), and diagnosis of diabetes (aOR 1.52, 95% CI 1.29-1.78, p < 0.001). CONCLUSION: This study found that approximately 20%-30% of patients receiving PD were exposed to PIPM from 2018 to 2019. Results from this study support the need to create medication management programs to decrease exposure to PIPM.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Silva Almodovar A, Donneyong M, Seiber E, et al. Prevalence of potentially inappropriately prescribed medications among older adults receiving peritoneal dialysis. Pharmacotherapy. 2025. PMID: 40035429. doi:10.1002/phar.70008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。